Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will
present data from clinical and preclinical studies of SNS-595 in advanced
leukemias at the upcoming American Society for Hematology (ASH) Annual
Meeting being held December 9-12, 2006 in Orlando, FL. SNS-595 is a
first-in-class cell-cycle modulator that is believed to act by targeting
proliferating cancer cells and inducing apoptosis, or programmed cell
death, during the S phase of the cell cycle.
Sunesis is conducting a Phase 1 clinical trial to examine the safety,
tolerability and pharmacokinetics of SNS-595 among patients with refractory
acute leukemia (primarily AML). Preliminary results from the Phase 1
clinical trial and from preclinical studies of SNS-595 will be presented in
two poster sessions on Sunday, December 10, 2006 starting at 9:00 a.m.
Eastern Time in Hall E1 of the West Building at the Orange County
Convention Center.
Session: Acute Myeloid Leukemia: Novel Therapies
A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agen SNS-595 in Advanced Leukemias
Session: Leukemias: Biology, Cytogenetics, and Molecular Markers in
Diagnosis and Prognosis: AML
SNS-595 a Novel S Phase Active Cytotoxic Acts Synergistically with Cytarabine To Reduce Bone Marrow Cellularity and Circulating Neutrophils
About Sunesis’ Oncology Programs
Sunesis has built a portfolio of preclinical- and development-stage
product candidates in oncology focused on novel pathways and targets,
including inhibition of the cell-cycle and survival signaling. Sunesis is
currently conducting Phase 2 and Phase 1 clinical trials in lung cancer and
acute myeloid leukemia for its lead compound, SNS-595. A second compound,
SNS-032, is in a Phase 1/2 clinical trial to examine the safety and
preliminary anti-tumor activity among patients with lung cancer, breast
cancer or melanoma. Sunesis is also conducting GLP toxicology studies of a
third drug candidate, an Aurora kinase inhibitor known as SNS-314. In
addition, in cooperation with Biogen Idec, Sunesis is developing novel
small molecule inhibitors of Raf kinase and other oncology kinases.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of novel small molecule
therapeutics for oncology and other serious diseases. Sunesis has built a
broad product candidate portfolio through internal discovery and
in-licensing of novel cancer therapeutics. Sunesis is advancing its product
candidates through in-house research and development efforts and strategic
collaborations with leading pharmaceutical and biopharmaceutical companies.
For additional information on Sunesis Pharmaceuticals, please visit
sunesis.
Forward-Looking Statements
This press release may contain forward-looking statements that involve
substantial risks and uncertainties. Sunesis may not actually achieve the
plans, intentions or expectations contained in such forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations contained in such forward-looking
statements. Sunesis does not assume any obligation to update any such
forward-looking statements. For further information on Sunesis
Pharmaceuticals, please visit sunesis.
Sunesis Pharmaceuticals, Inc.
sunesis